Related Experiment Video

Updated: May 5, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.2K

Metformin inhibits growth and sensitizes osteosarcoma cell lines to cisplatin through cell cycle modulation

Irene Quattrini1, Amalia Conti, Laura Pazzaglia

  • 1Laboratory of Experimental Oncology, Rizzoli Orthopaedic Institute, I-40136 Bologna, Italy.

Oncology Reports
|November 21, 2013
PubMed

Insights

Metformin enhances cisplatin

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Osteosarcoma (OS) is a prevalent bone cancer.
  • OS often exhibits resistance to conventional chemotherapy.

Purpose of the Study:

  • To investigate the combined effect of metformin and cisplatin on OS cell lines.
  • To determine if metformin can overcome cisplatin resistance in OS.

Main Methods:

  • Treatment of OS cell lines (U2OS, 143B, MG63) with metformin, cisplatin, or both.
  • Evaluation of cell viability, apoptosis, and cell cycle.
  • Protein expression analysis via Western blot.

Main Results:

  • Metformin demonstrated sensitivity across OS cell lines, impacting cell cycle and apoptosis.
  • Metformin sensitized cisplatin-resistant OS cells, indicating a synergistic effect.
  • Combined treatment showed enhanced anti-cancer effects.

Conclusions:

  • Metformin shows potential as an adjuvant therapy for osteosarcoma.
  • Combination therapy with metformin and cisplatin may offer a novel therapeutic strategy for OS.
  • Metformin inhibits tumor growth and potentiates cisplatin's efficacy in OS.

More Related Videos

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

20.2K
Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

12.4K

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
998
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K